Literature DB >> 3680565

The polymorphic metabolism of dextromethorphan.

J R Woodworth1, S R Dennis, L Moore, K S Rotenberg.   

Abstract

The ability of healthy male volunteers to metabolize a 30-mg oral dose of dextromethorphan (DM) was studied in 252 Americans. Two blood samples were collected at four and 24 hours after administration of the dose. The resulting plasma was analyzed for unchanged DM. The volunteers were classified as slow, intermediate, or fast metabolizers on the basis of plasma concentrations of DM. Further differentiation of slow and intermediate metabolizers was achieved by comparing the two-point estimates of elimination-rate constants. In the population studied, 84.3% were fast DM metabolizers, 6.8% were intermediate metabolizers, and 8.8% were slow metabolizers. Previous reports have related the slow DM metabolizers to slow debrisoquin metabolizers, but no such correlations have been achieved with intermediate DM metabolizers. These intermediate DM metabolizers may suggest a new polymorphism not related to debrisoquin or may suggest that "debrisoquin gene" regulation is more complex than originally suggested.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3680565     DOI: 10.1002/j.1552-4604.1987.tb02174.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  7 in total

1.  Pharmacokinetics of dimemorfan phosphate tablets in healthy Chinese volunteers.

Authors:  Yali Shen; Zhu Luo; Qin Yu; Ying Wang; Jin Xiang; Jia Miao
Journal:  Eur J Clin Pharmacol       Date:  2017-02-28       Impact factor: 2.953

2.  Dextromethorphan in nonketotic hyperglycinaemia: metabolic variation confounds the dose-response relationship.

Authors:  G L Arnold; M L Griebel; J L Valentine; D M Koroma; G L Kearns
Journal:  J Inherit Metab Dis       Date:  1997-03       Impact factor: 4.982

3.  Dextromethorphan metabolism in Jordanians: dissociation of dextromethorphan O-demethylation from debrisoquine 4-hydroxylation.

Authors:  Y M Irshaid; H F al-Hadidi; A Latif; F Awwadi; M al-Zoubi; N M Rawashdeh
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Oct-Dec       Impact factor: 2.441

4.  Oxidative polymorphism of dextromethorphan in a Burundi population.

Authors:  F Nsabiyumva; Y Furet; E Autret; A P Jonville; M Breteau
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

5.  Dextromethorphan pretreatment induces antipyrine clearance in the rat.

Authors:  C K Svensson; J A Ware
Journal:  Pharm Res       Date:  1988-07       Impact factor: 4.200

Review 6.  Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotyping.

Authors:  R T Coutts
Journal:  J Psychiatry Neurosci       Date:  1994-01       Impact factor: 6.186

7.  Randomized open-label trial of dextromethorphan in Rett syndrome.

Authors:  Constance L Smith-Hicks; Siddharth Gupta; Joshua B Ewen; Manisha Hong; Lisa Kratz; Richard Kelley; Elaine Tierney; Rebecca Vaurio; Genila Bibat; Abanti Sanyal; Gayane Yenokyan; Nga Brereton; Michael V Johnston; Sakkubai Naidu
Journal:  Neurology       Date:  2017-09-20       Impact factor: 9.910

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.